Moderna Inc (MRNA) Stock Forecast: Surge gives investors a shot in the arm as it prepares to deliver 1 billion doses in 2021
Premium|Take advantage of 60% OFF on your first month.
Grab this special offer, it's 7 months for FREE deal! And access ALL our articles and analysis.
You have reached your limit of 5 free articles for this month.
BLACK FRIDAY SALE! 60% OFF!
Grab this special offer, it's 7 months for FREE deal! And access ALL our articles and analysis.
CLAIM OFFER
-
NASDAQ:MRNA gains 4.56% as broader markets rally on Biden’s stimulus optimism.
-
The Swiss government becomes the latest country to order the COVID-19 vaccine from Moderna.
-
Moderna announces three new vaccines for the seasonal flu, Nipah virus, and HIV.
NASDAQ:MRNA is riding high after CEO Stephane Bancel announced that the company is slated to distribute over 1 billion doses of its COVID-19 vaccine candidate by the end of 2021. Investors embraced the news as shares of Moderna rose by 4.56% on Thursday to close the trading session at $129.72 as it continues to climb back from the late year beat down it took as new strains of the novel coronavirus started to emerge. The stock price dipped close to $100 on December 31st, but has rebounded nicely in the first couple trading weeks of 2021.
Switzerland announced it is the latest Moderna client as the European nation ordered 7.5 million doses of mRNA-1273, as the country battles through a surge of the virus at the end of 2020. In other Swiss news, drugmaker Lonza is awaiting approval to begin making active ingredients for mRNA-1273 which could boost Moderna’s supply chain in Europe, which remains one of the hardest hit regions in the world.
MRNA stock price
Moderna also announced that it has three new non COVID-19 vaccines coming down their pipelines for HIV, the seasonal flu, and Nipah virus, which should be ready to enter Phase 1 of the clinical trials at some point in 2021. The vaccines are said to include components that will help fight against SARS-CoV-2 as well, which is the virus strain that results in COVID-19. Perhaps word of Moderna’s success is spreading as a recent poll in the United States shows growing support in receiving the vaccine after initially it was met with skepticism by Americans.
-
NASDAQ:MRNA gains 4.56% as broader markets rally on Biden’s stimulus optimism.
-
The Swiss government becomes the latest country to order the COVID-19 vaccine from Moderna.
-
Moderna announces three new vaccines for the seasonal flu, Nipah virus, and HIV.
NASDAQ:MRNA is riding high after CEO Stephane Bancel announced that the company is slated to distribute over 1 billion doses of its COVID-19 vaccine candidate by the end of 2021. Investors embraced the news as shares of Moderna rose by 4.56% on Thursday to close the trading session at $129.72 as it continues to climb back from the late year beat down it took as new strains of the novel coronavirus started to emerge. The stock price dipped close to $100 on December 31st, but has rebounded nicely in the first couple trading weeks of 2021.
Switzerland announced it is the latest Moderna client as the European nation ordered 7.5 million doses of mRNA-1273, as the country battles through a surge of the virus at the end of 2020. In other Swiss news, drugmaker Lonza is awaiting approval to begin making active ingredients for mRNA-1273 which could boost Moderna’s supply chain in Europe, which remains one of the hardest hit regions in the world.
MRNA stock price
Moderna also announced that it has three new non COVID-19 vaccines coming down their pipelines for HIV, the seasonal flu, and Nipah virus, which should be ready to enter Phase 1 of the clinical trials at some point in 2021. The vaccines are said to include components that will help fight against SARS-CoV-2 as well, which is the virus strain that results in COVID-19. Perhaps word of Moderna’s success is spreading as a recent poll in the United States shows growing support in receiving the vaccine after initially it was met with skepticism by Americans.
Information on these pages contains forward-looking statements that involve risks and uncertainties. Markets and instruments profiled on this page are for informational purposes only and should not in any way come across as a recommendation to buy or sell in these assets. You should do your own thorough research before making any investment decisions. FXStreet does not in any way guarantee that this information is free from mistakes, errors, or material misstatements. It also does not guarantee that this information is of a timely nature. Investing in Open Markets involves a great deal of risk, including the loss of all or a portion of your investment, as well as emotional distress. All risks, losses and costs associated with investing, including total loss of principal, are your responsibility. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of FXStreet nor its advertisers.